OXiGENE Announces Publication of Key Data Showing Antitumor Activity of ZYBRESTAT(R) Combined With Bevacizumab

Published: Jun 07, 2012

SOUTH SAN FRANCISCO, Calif., June 6, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced the publication of key clinical data from a Phase 1 trial combining fosbretabulin (ZYBRESTAT®, combretastatin A4 phosphate, or CA4P), its lead vascular disrupting agent (VDA), with the anti-VEGF antibody bevacizumab (Avastin ®) to treat patients with advanced solid tumors, without the use of any cytotoxic chemotherapy, and receiving only the combined two anti-vascular drugs.

Back to news